← Oncology Approval Tracker

FDA DECISION ·

Venclexta combinations

venetoclax + azacitidine, decitabine or low-dose cytarabine · AbbVie

Traditional approvalTraditional conversionAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Newly diagnosed acute myeloid leukemia in adults aged 75 or older or with comorbidities preventing intensive induction chemotherapy, in combination with azacitidine, decitabine or low-dose cytarabine.

LAMPGEN ANALYSIS

Why it matters

Converted an accelerated indication to regular approval with randomized evidence for lower-intensity regimens.

What research teams should watch

Document why intensive induction is unsuitable and build tumor lysis, cytopenia and interaction checks into startup.

PRIMARY RECORDS

Sources